


PHARMACEUTICAL 2022


Lexaria Bioscience Corp. Rank 44 of 466







PHARMACEUTICAL 2022





The relative strengths and weaknesses of Lexaria Bioscience Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Lexaria Bioscience Corp. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 271%, being 194% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	12,443
Cost of Goods Sold	175
Intangible Assets	0
Liabilities, Current	153
Liabilities, Non-Current	50
Other Assets	824
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,501
Other Revenues	723
Property and Equipment	0
Research and Development	1,263
Selling, General and Administrative Expense	4,971

Output Variable	Value in 1000 USD
Assets	13,267
Liabilities	203
Expenses	6,410
Revenues	723
Stockholders Equity	13,064
Net Income	-4,186
Comprehensive Net Income	-4,186
Economic Capital Ratio	271%

